Canberra, Australia · Founded 2017 · Privately Held (backing)
Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. GPN Vaccines is based in Canberra, Australia and was founded in 2017. Its last reported valuation was $300 million in Jun 2024. It has raised $27.7 million across 1 recorded round; the latest was a $3.5 million seed round in Dec 2025.
Last reported valuation
$300.0M
Oct 2026
Priced at
—
Total raised
$27.7M
Last round
Seed Round
Dec 2025
No prints on record
No secondary trades in GPN Vaccines shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of GPN Vaccines with a free account
·Watch GPN Vaccines: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of GPN Vaccines stock.
